Explore
Validate
Learn20442-1-AP
antibody from Proteintech Group
Targeting: LPAR1
edg-2, EDG2, Gpcr26, GPR26, LPA1, Mrec1.3, rec.1.3, vzg-1
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 20442-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#20442-1-AP, RRID:AB_11183048
- Product name
- EDG2 antibody
- Antibody type
- Polyclonal
- Description
- EDG2 antibody (Cat. #20442-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Mannose-modified exosomes loaded with MiR-23b-3p target alveolar macrophages to alleviate acute lung injury in Sepsis.
Bronchopulmonary dysplasia demonstrates dysregulated autotaxin/lysophosphatidic acid signaling in a neonatal mouse model.
Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer.
S1PR3-driven positive feedback loop sustains STAT3 activation and keratinocyte hyperproliferation in psoriasis.
Prognostic value of LPAR1 expression and methylation in low-grade gliomas: a meta-analysis of TCGA and CGGA datasets and functional validation.
AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin.
Lin J, Yang L, Liu T, Zhao H, Liu Y, Shu F, Huang H, Liu W, Zhang W, Jiang L, Xiao S, Zheng Y, Xia Z
Journal of controlled release : official journal of the Controlled Release Society 2025 Mar 10;379:832-847
Journal of controlled release : official journal of the Controlled Release Society 2025 Mar 10;379:832-847
Bronchopulmonary dysplasia demonstrates dysregulated autotaxin/lysophosphatidic acid signaling in a neonatal mouse model.
Ha AW, Sudhadevi T, Jafri A, Mayer C, MacFarlane PM, Natarajan V, Harijith A
Pediatric research 2025 Jun;97(7):2462-2474
Pediatric research 2025 Jun;97(7):2462-2474
Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer.
Liu B, Peng Y, Su Y, Diao C, Cha L, Cheng R
Discover oncology 2025 Jun 13;16(1):1082
Discover oncology 2025 Jun 13;16(1):1082
S1PR3-driven positive feedback loop sustains STAT3 activation and keratinocyte hyperproliferation in psoriasis.
Lian P, Li L, Lu R, Zhang B, Wazir J, Gu C, Ma B, Pu W, Cao W, Huang Z, Su Z, Wang H
Cell death & disease 2025 Jan 20;16(1):31
Cell death & disease 2025 Jan 20;16(1):31
Prognostic value of LPAR1 expression and methylation in low-grade gliomas: a meta-analysis of TCGA and CGGA datasets and functional validation.
Chen H, Liang W, Li Z, Bian C, Wang H, Luo S, Xin Y, Feng W, Liang L
BMC cancer 2025 Dec 30;26(1):161
BMC cancer 2025 Dec 30;26(1):161
AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin.
Cai J, Wei J, Li S, Suber T, Zhao J
Mediators of inflammation 2017;2017:6893560
Mediators of inflammation 2017;2017:6893560
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The EDG2 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human EDG2. This antibody recognizes human,mouse,rat antigen. The EDG2 antibody has been validated for the following applications: ELISA, WB analysis.
